Detalhe da pesquisa
1.
The BTLA-HVEM axis restricts CAR T cell efficacy in cancer.
Nat Immunol
; 25(6): 1020-1032, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38831106
2.
Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapy.
Blood
; 143(2): 139-151, 2024 Jan 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37616575
3.
Immunologic predictors of vaccine responsiveness in patients with lymphoma and CLL.
J Infect Dis
; 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38437622
4.
Streamlined measurement of chimeric antigen receptor T-cell concentration, size, viability and two-color phenotyping during manufacturing.
Cytotherapy
; 26(5): 506-511, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38483365
5.
Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy.
Mol Ther
; 31(3): 686-700, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36641624
6.
Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study.
Mol Cancer
; 22(1): 200, 2023 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38066564
7.
Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel.
J Hematol Oncol
; 17(1): 19, 2024 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38644469
8.
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy.
Nat Med
; 30(4): 984-989, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38266761
9.
CAR T-Cell Immunotherapy in Minority Patients with Lymphoma.
NEJM Evid
; 3(4): EVIDoa2300213, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38776868
10.
Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines.
Blood Adv
; 8(3): 653-666, 2024 02 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38113468
11.
Apoptosis: a Janus bifrons in T-cell immunotherapy.
J Immunother Cancer
; 11(4)2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37055217
12.
Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer.
Cancer Discov
; 12(10): 2372-2391, 2022 10 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35904479
13.
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy.
Nat Med
; 28(4): 713-723, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35288695
14.
Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells.
Nat Med
; 27(5): 842-850, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33888899
15.
Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction.
Cancer Discov
; 10(4): 552-567, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32001516
16.
Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy.
Nat Med
; 29(11): 2954, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36253610